CommercialCoverageMedium impact
Screening for Lipid Disorders (CPB 0525, reviewed 2025-11-25)
Aetna·Cardiology, Internal Medicine, Family Medicine +2 more·Medical Policy
Effective date
Nov 25, 2025
We identified it
Aug 16, 2026
Summary
Aetna's updated CPB 0525 (effective 2025-11-25) clarifies coverage for lipid disorder screening, specifying that directly measured LDL-C is covered only for patients with triglycerides >250 mg/dL or type 2 diabetes, while breath isoprene, cholesterol skin testing, and direct VLDL measurement remain non-covered. Billing teams must ensure claims for CPT 83721 (direct LDL-C) include appropriate clinical documentation and ICD-10 codes indicating qualifying conditions.
Action Required
By 2025-11-25: Billing team must update claim submission logic to require one of the following ICD-10 codes when billing CPT 83721 (direct LDL-C measurement): E78.1 (Pure hyperglyceridemia), E78.2 (Mixed hyperlipidemia), or E08.00-E13.9 (Diabetes mellitus codes). Reject or hold claims for CPT 83721 without these qualifying diagnoses. Stop billing CPT 83719 (direct VLDL measurement) for all Aetna members—this code is non-covered. Update encounter forms and provider reminders to clarify that direct LDL-C requires documented hypertriglyceridemia (>250 mg/dL) or type 2 diabetes diagnosis. Ensure front-office staff verify patient's plan covers preventive cholesterol screening (asymptomatic screening exclusion applies to some plans). Claims submitted without proper clinical documentation or qualifying diagnoses will be denied.